PPM1H’s ability to reverse pathological Rab phosphorylation positions it as another potential therapeutic target for PD, with activity enhancers offering a novel approach to modulate LRRK2 signaling and mitigate disease progression. The gene discussed is PPM1H; the disease is Parkinson disease.